An unspoken rule among early-stage venture capital firms that “at least 50% of published studies, even those in top-tier academic journals, can't be repeated with the same conclusions by an industrial lab” has been recently reported (see Further information) and discussed. From: Nature Reviews Drug Discovery Believe it or not: how much can we rely on published data on potential drug targets? Florian Prinz, Thomas Schlange & Khusru Asadullah
50% be recently drug It's true that identification of drug target has been a very difficult challenge for several decades. The current drug development process of screening compounds and testing in animal and human without truly understanding the "mechanistic insight" hasn't been working well. Whoever develops a good method to find small molecule target is going to become famous.
【在 t*d 的大作中提到】 : An unspoken rule among early-stage venture capital firms that “at least 50% : of published studies, even those in top-tier academic journals, can't be : repeated with the same conclusions by an industrial lab” has been recently : reported (see Further information) and discussed. : From: : Nature Reviews Drug Discovery : Believe it or not: how much can we rely on published data on potential drug : targets? : Florian Prinz, Thomas Schlange & Khusru Asadullah
【在 g****1 的大作中提到】 : : 50% : be : recently : drug : It's true that identification of drug target has been a very difficult : challenge for several decades. The current drug development process of : screening compounds and testing in animal and human without truly : understanding the "mechanistic insight" hasn't been working well. Whoever : develops a good method to find small molecule target is going to become
【在 t*d 的大作中提到】 : An unspoken rule among early-stage venture capital firms that “at least 50% : of published studies, even those in top-tier academic journals, can't be : repeated with the same conclusions by an industrial lab” has been recently : reported (see Further information) and discussed. : From: : Nature Reviews Drug Discovery : Believe it or not: how much can we rely on published data on potential drug : targets? : Florian Prinz, Thomas Schlange & Khusru Asadullah
【在 t*d 的大作中提到】 : An unspoken rule among early-stage venture capital firms that “at least 50% : of published studies, even those in top-tier academic journals, can't be : repeated with the same conclusions by an industrial lab” has been recently : reported (see Further information) and discussed. : From: : Nature Reviews Drug Discovery : Believe it or not: how much can we rely on published data on potential drug : targets? : Florian Prinz, Thomas Schlange & Khusru Asadullah
【在 t*d 的大作中提到】 : An unspoken rule among early-stage venture capital firms that “at least 50% : of published studies, even those in top-tier academic journals, can't be : repeated with the same conclusions by an industrial lab” has been recently : reported (see Further information) and discussed. : From: : Nature Reviews Drug Discovery : Believe it or not: how much can we rely on published data on potential drug : targets? : Florian Prinz, Thomas Schlange & Khusru Asadullah
【在 t*d 的大作中提到】 : An unspoken rule among early-stage venture capital firms that “at least 50% : of published studies, even those in top-tier academic journals, can't be : repeated with the same conclusions by an industrial lab” has been recently : reported (see Further information) and discussed. : From: : Nature Reviews Drug Discovery : Believe it or not: how much can we rely on published data on potential drug : targets? : Florian Prinz, Thomas Schlange & Khusru Asadullah